Literature DB >> 25127858

Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.

Sergey V Ryzhov1, Michael W Pickup2, Anna Chytil2, Agnieszka E Gorska2, Qinkun Zhang3, Philip Owens2, Igor Feoktistov3, Harold L Moses2, Sergey V Novitskiy4.   

Abstract

There is growing evidence that generation of adenosine from ATP, which is mediated by the CD39/CD73 enzyme pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells. We have previously shown that the deletion of the TGF-β type II receptor gene (Tgfbr2) expression in myeloid cells is associated with decreased tumor growth, suggesting protumorigenic effect of TGF-β signaling. In this study, we tested the hypothesis that TGF-β drives differentiation of myeloid-derived suppressor cells into protumorigenic terminally differentiated myeloid mononuclear cells (TDMMCs) characterized by high levels of cell-surface CD39/CD73 expression. We found that TDMMCs represent a major cell subpopulation expressing high levels of both CD39 and CD73 in the tumor microenvironment. In tumors isolated from mice with spontaneous tumor formation of mammary gland and conditional deletion of the type II TGF-β receptor in mammary epithelium, an increased level of TGF-β protein was associated with further increase in number of CD39(+)CD73(+) TDMMCs compared with MMTV-PyMT/TGFβRII(WT) control tumors with intact TGF-β signaling. Using genetic and pharmacological approaches, we demonstrated that the TGF-β signaling mediates maturation of myeloid-derived suppressor cells into TDMMCs with high levels of cell surface CD39/CD73 expression and adenosine-generating capacity. Disruption of TGF-β signaling in myeloid cells resulted in decreased accumulation of TDMMCs, expressing CD39 and CD73, and was accompanied by increased infiltration of T lymphocytes, reduced density of blood vessels, and diminished progression of both Lewis lung carcinoma and spontaneous mammary carcinomas. We propose that TGF-β signaling can directly induce the generation of CD39(+)CD73(+) TDMMCs, thus contributing to the immunosuppressive, proangiogenic, and tumor-promoting effects of this pleiotropic effector in the tumor microenvironment.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25127858      PMCID: PMC4157098          DOI: 10.4049/jimmunol.1400578

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

3.  The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells.

Authors:  F Wilkin; X Duhant; C Bruyns; N Suarez-Huerta; J M Boeynaems; B Robaye
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

4.  ATP and control of intracellular growth of mycobacteria by T cells.

Authors:  David H Canaday; Reza Beigi; Richard F Silver; Clifford V Harding; W Henry Boom; George R Dubyak
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 5.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

Review 6.  Malignant cells, directors of the malignant process: role of transforming growth factor-beta.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

7.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

8.  Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms.

Authors:  Reza D Beigi; Sylvia B Kertesy; Gretchen Aquilina; George R Dubyak
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

9.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Authors:  Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

10.  Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin.

Authors:  Katayoun Alavi Jessen; Stephenie Y Liu; Clifford G Tepper; Juliana Karrim; Erik T McGoldrick; Andrea Rosner; Robert J Munn; Lawrence J T Young; Alexander D Borowsky; Robert D Cardiff; Jeffrey P Gregg
Journal:  Breast Cancer Res       Date:  2004-02-25       Impact factor: 6.466

View more
  59 in total

1.  A novel role of hepatic epithelial transforming growth factor-β signaling in cholangiocarcinogenesis.

Authors:  Man Liu; Myth T S Mok; Alfred S L Cheng
Journal:  Ann Transl Med       Date:  2016-03

2.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

3.  Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.

Authors:  Georgii Vasiukov; Tatiana Novitskaya; Andries Zijlstra; Philip Owens; Fei Ye; Zhiguo Zhao; Harold L Moses; Timothy Blackwell; Igor Feoktistov; Sergey V Novitskiy
Journal:  Cancer Res       Date:  2020-04-20       Impact factor: 12.701

Review 4.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

5.  Increased Expression of GARP in Papillary Thyroid Carcinoma.

Authors:  Xiaoxu Zhang; Miao Guo; Jing Yang; Yuxiao Zheng; Yanjie Xiao; Wei Liu; Fu Ren
Journal:  Endocr Pathol       Date:  2019-03       Impact factor: 3.943

6.  CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.

Authors:  Jieyao Li; Liping Wang; Xinfeng Chen; Lifeng Li; Yu Li; Yu Ping; Lan Huang; Dongli Yue; Zhen Zhang; Fei Wang; Feng Li; Li Yang; Jianmin Huang; Shuangning Yang; Hong Li; Xuan Zhao; Wenjie Dong; Yan Yan; Song Zhao; Bo Huang; Bin Zhang; Yi Zhang
Journal:  Oncoimmunology       Date:  2017-04-21       Impact factor: 8.110

7.  Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner.

Authors:  Denise Buenrostro; Kristin A Kwakwa; Nicole E Putnam; Alyssa R Merkel; Joshua R Johnson; James E Cassat; Julie A Sterling
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

Review 8.  Myeloid cells in the tumor microenvironment: Role of adenosine.

Authors:  Silvana Morello; Aldo Pinto; Corrado Blandizzi; Luca Antonioli
Journal:  Oncoimmunology       Date:  2015-12-03       Impact factor: 8.110

9.  Expression of adenosine receptors in monocytes from patients with bronchial asthma.

Authors:  Ksenia Yuryeva; Irina Saltykova; Ludmila Ogorodova; Natalya Kirillova; Evgeny Kulikov; Elena Korotkaya; Yulia Iakovleva; Igor Feoktistov; Alexey Sazonov; Sergey Ryzhov
Journal:  Biochem Biophys Res Commun       Date:  2015-07-30       Impact factor: 3.575

Review 10.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.